verapamil has been researched along with Anesthesia in 47 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Anesthesia: A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The objective of this study was to determine the influence of these agents on ketamine anesthesia in adult male mice." | 7.69 | Effects of cadmium and verapamil on ketamine-induced anesthesia in mice. ( Sangiah, S; Shen, Y, 1995) |
| "Verapamil pretreatment does not alter the increase in serum potassium induced by succinylcholine in normal dogs." | 5.27 | Verapamil does not alter succinylcholine-induced increases in serum potassium during halothane anesthesia in normal dogs. ( Gronert, GA; Nugent, M; Roth, JL, 1985) |
| "1 mg/kg of verapamil, administered immediately before anesthesia, significantly reduces the increase in peak heart rate and mean arterial blood pressure after electroconvulsive therapy." | 5.10 | Intravenous verapamil blunts hyperdynamic responses during electroconvulsive therapy without altering seizure activity. ( Imanaga, K; Inoue, T; Ogawa, R; Ogura, A; Shiga, T; Wajima, Z; Yoshikawa, T, 2002) |
| "1 mg/kg) on cardiovascular changes during tracheal extubation and emergence from anesthesia and compared the efficacy of the drug with that of diltiazem (0." | 5.08 | Attenuation of cardiovascular responses to tracheal extubation: verapamil versus diltiazem. ( Maekawa, N; Mikawa, K; Nishina, K; Obara, H, 1996) |
| " The objective of this study was to determine the influence of these agents on ketamine anesthesia in adult male mice." | 3.69 | Effects of cadmium and verapamil on ketamine-induced anesthesia in mice. ( Sangiah, S; Shen, Y, 1995) |
| ") was effective in heart failure models induced with high doses of propranolol or verapamil." | 3.67 | Cardiovascular pharmacology of 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride, a novel and potent cardiotonic agent with vasodilator properties. ( Kitada, Y; Narimatsu, A; Okushima, H; Satoh, N; Suzuki, R, 1987) |
| "Pretreatment with verapamil (an antagonist of the L-type calcium channel, 10 micromol/L) partially eliminated the above effects of UII (300 nmol/L) on the CSB." | 1.34 | Urotensin II inhibits carotid sinus baroreflex in anesthetized male rats. ( He, RR; Wu, YM; Xiao, L; Xue, HM, 2007) |
| "Atropine and verapamil were given separately to an additional 10 W/WV mice." | 1.33 | In vivo gastric and intestinal slow waves in W/WV mice. ( Chen, JD; Hou, X; Liu, J; Pasricha, PJ; Yin, J, 2005) |
| "Verapamil was infused at the rates of 1, 3 and 10 microg x kg(-1) x min(-1) (n=6), whereas propranolol was administered at a fixed rate of 10 microg x kg(-1) x min(-1) (n=6)." | 1.31 | Comparison of the electropharmacological effects of verapamil and propranolol in the halothane-anesthetized in vivo canine model under monophasic action potential monitoring. ( Hashimoto, K; Satoh, Y; Shiina, H; Sugiyama, A; Takahara, A, 2000) |
| "Pretreatment with lidocaine (5 mg/kg), verapamil (0." | 1.30 | Ischemia/reperfusion-induced arrhythmias in anaesthetized rats: a role of Na+ and Ca2+ influx. ( Dai, DZ; De Clerck, F; Lu, HR; Remeysen, P; Saels, A; Yang, P, 1999) |
| "Nitrendipine was equipotent with lacidipine in reducing the mean blood pressure (ED25 = 0." | 1.28 | The hemodynamic effects of lacidipine in anesthetized dogs: comparison with nitrendipine, amlodipine, verapamil, and diltiazem. ( Gambini, F; Gaviraghi, G; Micheli, D; Quartaroli, M; Tarter, G; Trist, DG, 1991) |
| "Flunarizine was similar." | 1.28 | Effects of verapamil, nifedipine and flunarizine on haemodynamics and regional blood flows in pentobarbitone-anaesthetized rats. ( Pang, CC; Waite, RP; Walker, MJ, 1990) |
| "Bepridil has a broader spectrum of activity and also acts at the atrial and ventricular levels." | 1.28 | Electrophysiological effects of bepridil and its quaternary derivative CERM 11888 in closed chest anaesthetized dogs: a comparison with verapamil and diltiazem. ( Lamar, JC; Leboeuf, J; Massingham, R; Ponsonnaille, J, 1989) |
| " Cumulative histamine dose-response curves were obtained on three groups each consisting of six dogs." | 1.27 | Different, dose-dependent effects of verapamil inhalation on histamine-induced bronchoconstriction in anaesthetized dogs. ( Brandt, HD; Bunn, AE; Krivoy, N, 1984) |
| "Verapamil was administered slowly intravenously until the mean arterial pressure was decreased by approximately 45 mm Hg." | 1.27 | Cardiovascular depression by verapamil: reversal by glucagon and interactions with propranolol. ( Jolly, SR; Kipnis, JN; Lucchesi, BR, 1987) |
| " Therefore, even though there is little variation in the pharmacokinetic parameters between adult dogs and puppies, there is a marked reduction in the sensitivity of the puppies to the ECG effects of verapamil." | 1.27 | Age-related changes in the pharmacodynamics of verapamil. ( Arnold, TH; Tackett, RL; Vallner, JJ, 1985) |
| "Treatment with propranolol (1 mg/Kg) and phentolamine (1 mg/Kg) which completely blocked cardiohemodynamic effect of 1 microgram/Kg of norepinephrine, markedly attenuated the effects of perhexiline on VR and PAF but not completely." | 1.26 | Effects of perhexiline on hemodynamics in anesthetized open-chest dogs. ( Hashimoto, K; O'Hara, N; Ono, H, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (59.57) | 18.7374 |
| 1990's | 14 (29.79) | 18.2507 |
| 2000's | 5 (10.64) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nihro, Y | 1 |
| Sogawa, S | 1 |
| Izumi, A | 1 |
| Sasamori, A | 1 |
| Sudo, T | 1 |
| Miki, T | 1 |
| Matsumoto, H | 1 |
| Satoh, T | 1 |
| Abe, K | 1 |
| Fujimoto, T | 1 |
| Niikura, Y | 1 |
| Akaishi, T | 1 |
| Misawa, M | 1 |
| Wajima, Z | 1 |
| Yoshikawa, T | 1 |
| Ogura, A | 1 |
| Imanaga, K | 1 |
| Shiga, T | 1 |
| Inoue, T | 1 |
| Ogawa, R | 1 |
| Hou, X | 1 |
| Yin, J | 1 |
| Liu, J | 1 |
| Pasricha, PJ | 1 |
| Chen, JD | 1 |
| Wu, YM | 1 |
| Xue, HM | 1 |
| Xiao, L | 1 |
| He, RR | 1 |
| van Poorten, JF | 1 |
| Dhasmana, KM | 1 |
| Kuypers, RS | 1 |
| Erdmann, W | 1 |
| Krivoy, N | 1 |
| Brandt, HD | 1 |
| Bunn, AE | 1 |
| Johnston, WE | 1 |
| Lowenstein, E | 1 |
| Moore, MM | 1 |
| Godin, DV | 1 |
| Fagbemi, O | 1 |
| Kane, KA | 1 |
| McDonald, FM | 1 |
| Parratt, JR | 1 |
| Rothaul, AL | 1 |
| Vasquez, EC | 1 |
| Mill, JG | 1 |
| Cabral, AM | 1 |
| Taylor, DG | 1 |
| Kowalski, TE | 1 |
| Ogawa, N | 1 |
| Kushida, H | 1 |
| Satoh, S | 1 |
| Hof, RP | 1 |
| Furuya, Y | 1 |
| Yokoyama, S | 1 |
| Morimoto, S | 1 |
| Nagara, M | 1 |
| Tanaka, S | 1 |
| Fujita, M | 1 |
| Watanabe, H | 1 |
| Furukawa, Y | 2 |
| Iwatsuki, K | 1 |
| Chiba, S | 2 |
| Ono, H | 1 |
| O'Hara, N | 1 |
| Hashimoto, K | 2 |
| Shen, Y | 2 |
| Sangiah, S | 2 |
| Richard, V | 1 |
| Tron, C | 1 |
| Blanc, T | 1 |
| Thuillez, C | 1 |
| Kline, JA | 1 |
| Tomaszewski, CA | 1 |
| Schroeder, JD | 1 |
| Raymond, RM | 1 |
| Nose, I | 1 |
| Kataoka, T | 1 |
| Honda, Y | 1 |
| Yamada, T | 1 |
| Ikeno, A | 1 |
| Fukuya, F | 1 |
| Minato, H | 1 |
| Takeyama, K | 1 |
| Hosoki, K | 1 |
| Karasawa, T | 1 |
| Yamazaki, K | 1 |
| Nakano, H | 1 |
| Kasama, M | 1 |
| Imamura, H | 1 |
| Mikawa, K | 1 |
| Nishina, K | 1 |
| Maekawa, N | 1 |
| Obara, H | 1 |
| Roder, JD | 1 |
| Lu, HR | 1 |
| Yang, P | 1 |
| Remeysen, P | 1 |
| Saels, A | 1 |
| Dai, DZ | 1 |
| De Clerck, F | 1 |
| Shiina, H | 1 |
| Sugiyama, A | 1 |
| Takahara, A | 1 |
| Satoh, Y | 1 |
| Vidrio, H | 1 |
| Quartaroli, M | 1 |
| Gambini, F | 1 |
| Tarter, G | 1 |
| Micheli, D | 1 |
| Trist, DG | 1 |
| Gaviraghi, G | 1 |
| Victory, JG | 1 |
| Foëx, P | 1 |
| Leone, BJ | 1 |
| Waite, RP | 1 |
| Pang, CC | 1 |
| Walker, MJ | 1 |
| Piascik, MT | 1 |
| Collins, R | 1 |
| Butler, BT | 1 |
| Leboeuf, J | 1 |
| Lamar, JC | 1 |
| Massingham, R | 1 |
| Ponsonnaille, J | 1 |
| Wauquier, A | 1 |
| Melis, W | 1 |
| Janssen, PA | 1 |
| Abdel-Rahman, AR | 1 |
| Ingenito, AJ | 1 |
| Allely, MC | 1 |
| Alps, BJ | 1 |
| Jolly, SR | 1 |
| Kipnis, JN | 1 |
| Lucchesi, BR | 1 |
| Narimatsu, A | 1 |
| Kitada, Y | 1 |
| Satoh, N | 1 |
| Suzuki, R | 1 |
| Okushima, H | 1 |
| Reimer, KA | 1 |
| Jennings, RB | 1 |
| Cobb, FR | 1 |
| Murdock, RH | 1 |
| Greenfield, JC | 1 |
| Becker, LC | 1 |
| Bulkley, BH | 1 |
| Hutchins, GM | 1 |
| Schwartz, RP | 1 |
| Bailey, KR | 1 |
| Siegl, PK | 1 |
| Wenger, HC | 1 |
| Chapman, RW | 1 |
| Marmo, E | 2 |
| Jones, RM | 1 |
| Cashman, JN | 1 |
| Casson, WR | 1 |
| Broadbent, MP | 1 |
| Arnold, TH | 1 |
| Vallner, JJ | 1 |
| Tackett, RL | 1 |
| Roth, JL | 1 |
| Nugent, M | 1 |
| Gronert, GA | 1 |
| Brichard, G | 1 |
| Zimmerman, PE | 1 |
| Di Mezza, F | 1 |
| Reuter, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Single Dose of Tramadol on Extubation Response and Quality of Emergence(Cough and Nausea Vomiting) Following Supratentorial Intracranial Surgery[NCT02964416] | Phase 4 | 80 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
If there is any episode of bronchospasm or laryngospasm, it will be noted if it occured during emergence and for 6 hours post operatively. Absence of it will be considered as smooth emergence (NCT02964416)
Timeframe: at the time of extubation till 6 hours postoperatively
| Intervention | Number of Patients (Number) |
|---|---|
| Tramadol | 0 |
| Placebo | 0 |
Requirement of analgesia will be recorded at recovery room, 2, 4 and 6 hours postoperatively. If there is any need of analgesic, it will be noted and will be considered as one of the determinants of poor quality of emergence. (NCT02964416)
Timeframe: At Recovery room, 2, 4 and 6 hours postoperatively
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Recovery Room | 2h | 4h | 6h | |
| Placebo | 3 | 23 | 4 | 7 |
| Tramadol | 5 | 15 | 3 | 6 |
Convulsions will be recorded at Recovery Room, 2, 4 and 6 hours postoperatively.If there is any episode of convulsion, it will be noted. Absence of it will be considered as smooth emergence. (NCT02964416)
Timeframe: at Recovery Room, 2, 4 and 6 hours postoperatively
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Recovery Room | 2h | 4h | 6h | |
| Placebo | 0 | 0 | 0 | 0 |
| Tramadol | 0 | 0 | 1 | 0 |
"Post operative Glasgow Coma Scale (GCS) will be recorded at Recovery Room, 2, 4 and 6 hours postoperatively. If there is any deterioration in GCS less than 8/15, Patients will be intubated.~GCS categories <8 Low GCS 9-12 Intermediate GCS 13-15 Full GCS" (NCT02964416)
Timeframe: at Recovery Room, 2, 4 and 6 hours postoperatively
| Intervention | Number of Patients (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recovery Room : <8 | Recovery Room : 9-12 | Recovery Room : 13-15 | 2h : <8 | 2h : 9-12 | 2h : 13-15 | 4h : <8 | 4h : 9-12 | 4h : 13-15 | 6h : <8 | 6h : 9-12 | 6h : 13-15 | |
| Placebo | 0 | 0 | 41 | 0 | 1 | 40 | 1 | 0 | 40 | 1 | 0 | 40 |
| Tramadol | 0 | 1 | 38 | 0 | 1 | 38 | 0 | 0 | 39 | 0 | 0 | 39 |
Post operative nausea vomiting will be recorded at RR, 2, 4 and 6 hours postoperatively. If there is any episode of PONV it will be noted. Absence of it will be considered as smooth emergence (NCT02964416)
Timeframe: at Recovery Room , 2, 4 and 6 hours postoperatively
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Recovery Room | 2h | 4h | 6h | |
| Placebo | 0 | 3 | 1 | 1 |
| Tramadol | 0 | 3 | 0 | 0 |
Diastolic blood pressure will be recorded at 1 minute before giving the reversal (glycopyrolate and neostigmine) and then 1,2,5,10,20,30 minutes ,1,2,4 and 6 hours after extubation. If values of blood pressure rise more than 20% from baseline values injection Metoprolol 1mg (beta blocker) bolus will be used and titrated according to response. The study will end at 6 hours post extubation. (NCT02964416)
Timeframe: Diastolic BP from the time of extubation till 6 hours post operatively
| Intervention | mm Hg (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base line | 1min Before Extubation | 1min After Extubation | 2 min | 5min | 10min | 20min | 30min | 1h | 2h | 4h | 6h | |
| Placebo | 77.83 | 78.65 | 85.78 | 82.41 | 78.59 | 78.32 | 76.73 | 76.93 | 75.33 | 75.89 | 78.00 | 74.89 |
| Tramadol | 75.92 | 77.30 | 83.97 | 79.19 | 78.68 | 77.37 | 78.19 | 77.14 | 76.39 | 75.71 | 74.85 | 75.26 |
Heart rate will be recorded at 1 minute before giving the reversal (glycopyrolate and neostigmine) and then 1,2,5,10,20,30 minutes ,1,2,4 and 6 hours after extubation. If haemodynamic values of heart rate rise more than 20% from baseline values injection Metoprolol 1mg (beta blocker) bolus will be used and titrated according to response. The study will end at 6 hours post extubation. (NCT02964416)
Timeframe: HR from the time of extubation till 6 hours post operatively
| Intervention | bpm (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 1min Before Extubation | 1min After Extubation | 2 min | 5min | 10min | 20min | 30min | 1h | 2h | 4h | 6h | |
| Placebo | 79.37 | 91.41 | 98.54 | 93.50 | 90.00 | 86.70 | 83.38 | 84.10 | 82.46 | 81.97 | 81.23 | 78.20 |
| Tramadol | 82.26 | 89.30 | 93.61 | 89.61 | 86.27 | 86.26 | 82.44 | 81.92 | 79.53 | 80.03 | 78.94 | 79.65 |
Systolic blood pressure will be recorded at 1 minute before giving the reversal (glycopyrolate and neostigmine) and then 1,2,5,10,20,30 minutes ,1,2,4 and 6 hours after extubation. If values of blood pressure rise more than 20% from baseline values injection Metoprolol 1mg (beta blocker) bolus will be used and titrated according to response. The study will end at 6 hours post extubation. (NCT02964416)
Timeframe: Systolic BP from the time of extubation till 6 hours post operatively
| Intervention | mm Hg (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 1min Before Extubation | 1min After Extubation | 2 min | 5min | 10min | 20min | 30min | 1h | 2h | 4h | 6h | |
| Placebo | 132.34 | 134.29 | 143.70 | 139.77 | 133.37 | 131.59 | 133.15 | 132.10 | 129.80 | 125.74 | 125.81 | 122.61 |
| Tramadol | 128.55 | 132.63 | 141.81 | 134.89 | 130.05 | 126.95 | 127.86 | 127.19 | 128.11 | 127.76 | 127.35 | 122.97 |
"If there is any episodes of denaturation (Oxygen saturation <92%), it will be noted it it is occurring during emergence.~Absence of it will be considered as smooth emergence" (NCT02964416)
Timeframe: at the time of extubation
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| at resumption of spontaneous breathing | at the time of obeying of verbal commands | at the time of cuff deflation | at the time of extubation | 2 min after extubation | |
| Placebo | 0 | 0 | 0 | 0 | 0 |
| Tramadol | 0 | 0 | 0 | 0 | 0 |
"Cough will be described on following scale 5 = No coughing or straining, 4 = Very smooth minimal coughing, 3 = Moderate coughing, 2 = Marked coughing or straining,~1 = Poor extubation~Cough will be recorded on the above mentioned scale by resident/consultant at following time intervals of emergence~At resumption of spontaneous breathing,~Ability to respond to verbal commands~At cuff deflation~At extubation~2 minutes after extubation. It will be noted if it occurs during emergence at the above mentioned time intervals. Absence of it will be considered as smooth emergence." (NCT02964416)
Timeframe: Cough at the time of emergence
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At resumption of spontaneous breathing72201515 | At resumption of spontaneous breathing72201516 | Ability to respond to verbal commands72201516 | Ability to respond to verbal commands72201515 | At cuff deflation72201516 | At cuff deflation72201515 | At extubation72201516 | At extubation72201515 | 2 minutes after extubation72201515 | 2 minutes after extubation72201516 | |||||||||||||||||||||||||||||||||||||||||
| Poor extubation | Marked coughing or straining | Moderate coughing | Very smooth minimal coughing | No coughing or straining | ||||||||||||||||||||||||||||||||||||||||||||||
| Tramadol | 33 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 36 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Tramadol | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Tramadol | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Tramadol | 34 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 37 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 33 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Tramadol | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Tramadol | 32 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 32 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Tramadol | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Tramadol | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Tramadol | 36 | |||||||||||||||||||||||||||||||||||||||||||||||||
1 review available for verapamil and Anesthesia
| Article | Year |
|---|---|
Calcium channel blocking drugs.
Topics: Anesthesia; Angina Pectoris; Animals; Calcium; Calcium Channel Blockers; Cardiomyopathy, Hypertrophi | 1983 |
2 trials available for verapamil and Anesthesia
| Article | Year |
|---|---|
Intravenous verapamil blunts hyperdynamic responses during electroconvulsive therapy without altering seizure activity.
Topics: Adult; Aged; Anesthesia; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Double-Blind | 2002 |
Attenuation of cardiovascular responses to tracheal extubation: verapamil versus diltiazem.
Topics: Adult; Anesthesia; Blood Pressure; Calcium Channel Blockers; Diastole; Diltiazem; Female; Genitalia, | 1996 |
44 other studies available for verapamil and Anesthesia
| Article | Year |
|---|---|
3-O-alkylascorbic acids as free radical quenchers. 3. Protective effect on coronary occlusion-reperfusion induced arrhythmias in anesthetized rats.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Ascorbic Acid; Blood Pressure; Fr | 1992 |
Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral amygdala-dentate gyrus pathway of anesthetized rats.
Topics: Amygdala; Anesthesia; Animals; Calcium Channels, L-Type; Dentate Gyrus; Electric Stimulation; GABA A | 2009 |
In vivo gastric and intestinal slow waves in W/WV mice.
Topics: Anesthesia; Animals; Atropine; Biological Clocks; Central Nervous System; Electrophysiology; Enteric | 2005 |
Urotensin II inhibits carotid sinus baroreflex in anesthetized male rats.
Topics: Anesthesia; Animals; Baroreflex; Carotid Sinus; Male; NG-Nitroarginine Methyl Ester; Peptides, Cycli | 2007 |
Verapamil and reversal of vecuronium neuromuscular blockade.
Topics: Aged; Anesthesia; Drug Interactions; Female; Humans; Neuromuscular Blocking Agents; Neuromuscular Ju | 1984 |
Different, dose-dependent effects of verapamil inhalation on histamine-induced bronchoconstriction in anaesthetized dogs.
Topics: Aerosols; Airway Resistance; Anesthesia; Animals; Atropine; Bronchi; Dogs; Dose-Response Relationshi | 1984 |
The protective effects of D-600 and propranolol on reperfusion injury in the anaesthetized rabbit.
Topics: 4-Nitrophenylphosphatase; Adenosine Triphosphate; Anesthesia; Animals; Coronary Circulation; Gallopa | 1984 |
The effects of verapamil, prenylamine, flunarizine and cinnarizine on coronary artery occlusion-induced arrhythmias in anaesthetized rats.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Calcium Channel B | 1984 |
Effects of verapamil on blood pressure and heart rate in neurogenic hypertensive rats.
Topics: Anesthesia; Animals; Blood Pressure; Heart Rate; Hypertension; Male; Pressoreceptors; Rats; Rats, In | 1984 |
Comparison of calcium channel inhibitors on vagal heart rate responses elicited by arterial baroreceptor reflexes in anesthetized dogs.
Topics: Acetylcholine; Anesthesia; Animals; Calcium Channel Blockers; Diltiazem; Dogs; Heart Rate; In Vitro | 1984 |
Effect of verapamil on renal vasoconstriction induced by angiotensin II, norepinephrine or renal nerve stimulation in anesthetized dogs.
Topics: Anesthesia; Angiotensin II; Animals; Dogs; Electric Stimulation; Female; Kidney; Male; Norepinephrin | 1984 |
The calcium antagonists PY 108-068 and verapamil diminish the effects of angiotensin II: sites of interaction in the peripheral circulation of anaesthetized cats.
Topics: Anesthesia; Angiotensin II; Animals; Calcium Channel Blockers; Cardiac Output; Cats; Hemodynamics; N | 1984 |
[Effects of verapamil on the normal and ischemic heart].
Topics: Anesthesia; Animals; Coronary Circulation; Dogs; Hemodynamics; Myocardial Infarction; Verapamil | 1983 |
Effects of nicardipine on the cross-perfused canine atrium.
Topics: Anesthesia; Animals; Chlorides; Dogs; Female; Heart; Heart Rate; Male; Manganese; Manganese Compound | 1981 |
Effects of perhexiline on hemodynamics in anesthetized open-chest dogs.
Topics: Anesthesia; Animals; Blood Circulation; Blood Flow Velocity; Blood Pressure; Cardiac Output; Dogs; D | 1981 |
Effects of cadmium and verapamil on ketamine-induced anesthesia in mice.
Topics: Anesthesia; Anesthetics, Dissociative; Animals; Body Burden; Cadmium; Calcium Channel Blockers; Cyto | 1995 |
Infarct size-limiting properties of Ro 40-5967, a novel nondihydropyridine calcium channel, in anesthetized rats: comparison with verapamil.
Topics: Anesthesia; Animals; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Heart Rate; Hemodynam | 1995 |
Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine.
Topics: Anesthesia; Animals; Antidotes; Blood Glucose; Cardiovascular Diseases; Disease Models, Animal; Dogs | 1993 |
In vitro and in vivo electrocardiographic evaluation of the novel calcium antagonist monatepil on cardiac conduction system.
Topics: Anesthesia; Animals; Blood Pressure; Bundle of His; Calcium Channel Blockers; Dibenzothiepins; Dilti | 1993 |
Inhibition of the subsidiary pacemaker activity by zatebradine, an If inhibitor, in the anesthetized dog heart.
Topics: Anesthesia; Animals; Atrioventricular Node; Benzazepines; Cardiotonic Agents; Dogs; Verapamil | 1995 |
The effects of verapamil and lidocaine on the duration of propofol and xylazine-ketamine anesthesia in broiler chickens.
Topics: Aging; Analysis of Variance; Anesthesia; Anesthetics; Animals; Calcium Channel Blockers; Chickens; D | 1996 |
Ischemia/reperfusion-induced arrhythmias in anaesthetized rats: a role of Na+ and Ca2+ influx.
Topics: Amiloride; Anesthesia; Animals; Arrhythmias, Cardiac; Benzothiazoles; Blood Pressure; Calcium; Calci | 1999 |
Comparison of the electropharmacological effects of verapamil and propranolol in the halothane-anesthetized in vivo canine model under monophasic action potential monitoring.
Topics: Action Potentials; Adrenergic beta-Antagonists; Anesthesia; Animals; Atrioventricular Node; Blood Pr | 2000 |
Interaction with pyridoxal as a possible mechanism of hydralazine hypotension.
Topics: Anesthesia; Animals; Blood Pressure; Cinnarizine; Dose-Response Relationship, Drug; Hydralazine; Inj | 1990 |
The hemodynamic effects of lacidipine in anesthetized dogs: comparison with nitrendipine, amlodipine, verapamil, and diltiazem.
Topics: Amlodipine; Anesthesia; Animals; Blood Gas Analysis; Blood Pressure; Calcium Channel Blockers; Coron | 1991 |
End systolic pressure-length relations in halothane anaesthetised dogs: effects of regional ischaemia and inotropic agents.
Topics: Anesthesia; Animals; Calcium; Coronary Disease; Dogs; Female; Halothane; Male; Myocardial Contractio | 1991 |
Effects of verapamil, nifedipine and flunarizine on haemodynamics and regional blood flows in pentobarbitone-anaesthetized rats.
Topics: Anesthesia; Animals; Calcium Channel Blockers; Cardiac Output; Electrocardiography; Flunarizine; Hea | 1990 |
Stereoselective and nonstereoselective inhibition exhibited by the enantiomers of verapamil.
Topics: Anesthesia; Animals; Blood Pressure; Brain; Calcium Channels; In Vitro Techniques; Membranes; Muscle | 1990 |
Electrophysiological effects of bepridil and its quaternary derivative CERM 11888 in closed chest anaesthetized dogs: a comparison with verapamil and diltiazem.
Topics: Anesthesia; Animals; Bepridil; Blood Pressure; Calcium Channel Blockers; Diltiazem; Dogs; Electrocar | 1989 |
Long-term neurological assessment of the post-resuscitative effects of flunarizine, verapamil and nimodipine in a new model of global complete ischaemia.
Topics: Anesthesia; Animals; Behavior, Animal; Disease Models, Animal; Electroencephalography; Electromyogra | 1989 |
Similarities and differences in the effects of verapamil, diltiazem and nifedipine on arterial baroreflexes of anesthetized cats.
Topics: Anesthesia; Animals; Benzazepines; Blood Pressure; Carotid Arteries; Cats; Diltiazem; Electric Stimu | 1985 |
The effects of the novel anti-anginal compound RS 43285 on myocardial conduction in the anaesthetized dog.
Topics: Acetanilides; Anesthesia; Angina Pectoris; Animals; Atrioventricular Node; Dogs; Electrocardiography | 1988 |
Cardiovascular depression by verapamil: reversal by glucagon and interactions with propranolol.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Blood Pressure; Dogs; Drug Interactions; Glucagon; Hear | 1987 |
Cardiovascular pharmacology of 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride, a novel and potent cardiotonic agent with vasodilator properties.
Topics: Anesthesia; Animals; Cardiotonic Agents; Dogs; Female; Heart Failure; Hemodynamics; Hindlimb; Male; | 1987 |
Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study. Comparison of unconscious and conscious dog models.
Topics: Anesthesia; Animal Testing Alternatives; Animals; Arterial Occlusive Diseases; Coronary Circulation; | 1985 |
Cardiovascular responses to an isosterically modified prostaglandin analog in the anesthetized dog.
Topics: Anesthesia; Animals; Dinoprost; Dogs; Epoprostenol; Female; Hemodynamics; Hydralazine; Male; Nifedip | 1985 |
Effect of verapamil on ventilation and chemical control of breathing in anesthetized rats.
Topics: Anesthesia; Animals; Carbon Dioxide; Hypoxia; Male; Rats; Respiration; Vagotomy; Verapamil | 1985 |
On the mechanism of the anti-hypertensive effect of Ca++-blockers.
Topics: Anesthesia; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dogs; Heart | 1986 |
Verapamil potentiation of neuromuscular blockade: failure of reversal with neostigmine but prompt reversal with edrophonium.
Topics: Anesthesia; Cardiomyopathy, Hypertrophic; Cholecystectomy; Drug Synergism; Edrophonium; Humans; Male | 1985 |
Age-related changes in the pharmacodynamics of verapamil.
Topics: Administration, Oral; Aging; Anesthesia; Animals; Blood Pressure; Dogs; Electrocardiography; Electro | 1985 |
Verapamil does not alter succinylcholine-induced increases in serum potassium during halothane anesthesia in normal dogs.
Topics: Anesthesia; Animals; Dogs; Halothane; Potassium; Succinylcholine; Verapamil | 1985 |
Treatment of arrhythmias with verapamil.
Topics: Adult; Anesthesia; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Nitriles; Vasodilator Agent | 1970 |
[Interactions between beta-adrenolytic agents and narcotics. Experimental research].
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Drug Synergism; Ethanolamines; Nitriles; Pregnanediones | 1970 |
[Effect of quinidine, iproveratril, lidocaine and sparteine on ECG and circulatory system of the anesthetized cat].
Topics: Anesthesia; Animals; Blood Pressure; Cats; Drug Interactions; Electrocardiography; Heart; Heart Rate | 1973 |